Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study

•Regdanvimab significantly reduced progression to severe/critical disease or death.•Supplemental oxygen use was significantly shorter with regdanvimab.•Duration of hospitalization was significantly shorter with regdanvimab.•Regdanvimab was well tolerated with no new safety events identified.•Medical utilization cost significantly reduced in regdanvimab group.